VIP

VIP – Vasoactive Intestinal Peptide for Immune, Gut, and Neurovascular Research

Vasoactive Intestinal Peptide (VIP) is a naturally occurring peptide hormone and neurotransmitter produced in the gut, lungs, pancreas, and brain, particularly within the enteric and central nervous systems. Through VPAC1 and VPAC2 G‑protein–coupled receptors, this multifunctional peptide regulates smooth‑muscle tone, epithelial barrier function, immune balance, and neurovascular signaling, making it a versatile tool in inflammatory, gastrointestinal, pulmonary, and neuroimmune research.

Key features

• Immune and anti‑inflammatory modulation: VIP suppresses pro‑inflammatory cytokines (e.g., TNF‑α, IL‑6, IL‑12), promotes regulatory T‑cell responses, and helps rebalance Th1/Th2 immunity in autoimmune and chronic‑inflammation models.

• Gut barrier and motility support: In the GI tract, VIP relaxes smooth muscle, enhances intestinal water and electrolyte secretion, supports tight‑junction integrity, and modulates secretory and motility patterns relevant to IBD, IBS, and CIRS‑type models.

• Neuroprotective and neuroendocrine actions: VIP acts as a neuromodulator in the brain, influencing circadian rhythm, neuroprotection, and neurogenesis, while impacting mood, autonomic balance, and neuroimmune communication.

• Vascular and pulmonary effects: As a potent vasodilator and bronchodilator, VIP regulates blood flow and airway tone and has been studied in pulmonary hypertension, asthma, COPD, and fibrotic lung‑disease models.

  
  

Research applications

VIP is utilized in experimental systems exploring:

• Autoimmune and inflammatory disease, including rheumatoid arthritis, inflammatory bowel disease, sarcoidosis, and chronic inflammatory response–like syndromes.

• Gut integrity and microbiome‑adjacent research, assessing permeability, tight‑junction proteins, mucus production, motility, and neurogastroenterology endpoints.

• Neuroprotection and neurodegeneration, where VIP’s effects on microglia, oxidative stress, and neuronal survival are evaluated in Parkinson’s, ALS, and other CNS models.

• Pulmonary and vascular disorders, including asthma, COPD, pulmonary fibrosis, and pulmonary hypertension, with outcomes in airway reactivity, remodeling, and hemodynamics.

  
  

Recommended handling

• For controlled laboratory research use only, by qualified professionals.

• Store in a cool, dry environment away from light; follow institutional SOPs for peptide storage, reconstitution, aliquoting, and disposal.

• Investigators should consult current literature for receptor‑selective questions (VPAC1 vs VPAC2), dosing, and timing relative to immune, respiratory, or gut‑function endpoints.

  
  

Important disclaimer

All compounds sold by Rocky Peptide Chain, including VIP, are for research use only. They are not intended for human consumption, medical use, diagnostic purposes, or treatment of any disease or condition. No claims are made or implied regarding symptom relief, inflammation reduction, cognitive improvement, or therapeutic benefit. Researchers are solely responsible for appropriate handling, experimental design, and compliance with all applicable regulations.